Skip to main content
Drug bottle and Pill

Compare Uptravi vs. Tyvaso

Head-to-head comparisons of medication uses, side effects, warnings, and more.

Key takeaways

Uptravi (selexipag) and Tyvaso (treprostinil) are both medications used to treat pulmonary arterial hypertension (PAH), but they have some key differences. Uptravi is a prostacyclin agonist taken orally as a tablet or through an intravenous (IV) injection, while Tyvaso is a man-made version of prostacyclin, a hormone your body naturally makes. It is available as an inhalation treatment through a nebulizer or dry powdered inhaler (DPI). Uptravi is taken twice a day, whereas Tyvaso needs to be used four times a day. Uptravi can cause side effects like headache, diarrhea, and nausea, while Tyvaso commonly causes cough, headache, and throat irritation. Additionally, Uptravi can cause excess fluid in the lungs, while Tyvaso can cause low blood pressure and increases the risk of bleeding.

Browse medications

View All

Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.